4 results about "Recombinant bcg" patented technology

The application discloses a recombinant bacillus Calmette-Guerin (BCG) strain and application of the recombinant BCG strain in preparation of a tumor vaccine, wherein the recombinant BCG strain comprises an HPV16 E7 antigen gene with a nucleotide sequence as shown in SEQ ID NO:1; a cytolysin ClyA gene is further fused with the HPV16 E7 to be expressed, and a rBCG-ClyA+E7 recombinant strain is constructed; the recombinant BCG strain rBCG-E7 or rBCG-ClyA+E7 is applied in preparation of a vaccine for treating cervical cancer solid tumors; the anti-tumor effect is verified in a solid tumor model through a subcutaneous injection mode; the ClyA significantly improves the expression efficiency of an exogenous antigen in the BCG, and simultaneously enhances the presentation efficiency of an antigen presenting cell; the recombinant vaccine effectively activates an anti-tumor immune response, and does not cause obvious toxic side effects, thereby providing a safe and effective candidate strategy for immunotherapy of cervical cancer and other HPV related solid tumors.

The application provides an improved recombinant bacillus Calmette-Guerin (BCG) and application thereof, and belongs to the technical field of biotechnology. The BCG ManLAM mutant strain is obtained by knocking out the coding gene of a key glycosyltransferase MptC for synthesizing the terminal mannose of ManLAM in the BCG, and is used as the improved BCG. Compared with the wild-type BCG, the improved BCG constructed in the application can promote the functional maturation of dendritic cells and improve the anti-tuberculosis infection immune response, can be used as a new vaccine for preventing tuberculosis or as an active ingredient for preparing a medicine for preventing and treating tuberculosis, and has a wide prospect in the development and clinical application of the new vaccine. In addition, the application provides a new tool and idea for the prevention and treatment of tuberculosis.

Recombinant BCG, a preparation method therefor and an application thereof. A shuttle plasmid that can express a FimH protein on the surface of BCG is constructed, and a gene fragment that expresses the FimH protein is transformed into wild-type BCG to thereby obtain recombinant BCG. Upon verification, the recombinant BCG can express the FimH protein on the surface of BCG; therefore, the BCG can specifically bind to subjects that can selectively bind to the FimH protein. The recombinant BCG can also enhance the local innate immune effect and adaptive immune effect induced by BCG and the anti-tumor effect of peripheral blood mononuclear cells, and also significantly improves the effect of BCG against bladder tumors, and is used to treat bladder tumors.

This invention discloses a BCG biomimetic vesicle and its application in the preparation of tumor nanovaccines, belonging to the field of tumor vaccines. The invention uses BCG strains or recombinant BCG strains as raw materials, and through a reduction-chelation-enzymatic hydrolysis synergistic cell disruption and high-pressure homogenization recombination process, produces BCG biomimetic vesicles and membrane-anchored tumor antigen genes. The BCG biomimetic vesicles prepared with BCG strains can efficiently induce BMDCs to establish training immune memory, while simultaneously promoting the differentiation of memory T cells and NK cell activation in lymph nodes, indirectly stimulating acquired immune responses, thereby inhibiting cervical cancer tumor growth. The BCG biomimetic vesicles prepared with recombinant BCG strains can synergistically activate lymph node acquired immunity and training immunity-mediated innate immunity, inhibiting the growth of HPV-related subcutaneous xenografts. This invention provides a candidate strategy for the immunotherapy of HPV-related tumors, with clear clinical application prospects and industrial value.